LONG-ACTING TREATMENTS: PEOPLE’S EXPECTATIONS AND ATTENDING PHYSICIANS’ PREPAREDNESS. ARE WE READY TO MANAGE IT?

Marta Celesia1, Manuela Ceccarelli2, Michele Trezzi2, Alessandra Tzaninis4, Margherita Ericono1, Paola Cinque6, Emanuele Foca2, Diego Ripamonti8, Salvatore Martin10, Silvia Nozza5, Cristina Gervasoni11, Chiara Dentone11, Giovanni Cenderello12, Andrea Calcagno15, Giancarlo Orefice16, Annamaria Cattelan7, Evelina Tacconelli16, Francesca Vichi17, Annalisa Saracino18, Sergio Lo Caputo19, Giuseppe De Socio20, Giuliana Guadagnino21, Giustino Parruti27, Antonella Cingoli23, Marco Borderi24, Cristina Mussini25, Gabriella Dettorre24, Paolo Maggi24, Tiziana Quirino27, Giordano Madeddu28, Amedeo Capetti22, Antonio Di Blasi29, Bruno Capocci22, Benedetto Maurizio Celesia30.

Introduction

Antiretroviral treatment is evolving towards new approaches for a long life smart management of HIV infection. Recently a randomized clinical trial confirmed tolerability and efficacy of bi-monthly injectable combination of cabotegravir and rilpivirine. Long acting injectable drugs are not so far from extensive clinical use and the spread of this new therapeutic strategy could represent, at the same time, an answer for some needs of the patients (stigma, adherence, treatment fatigue), but a big challenge for the national health system.

Available studies about long-acting drugs were limited to evaluated patients’ related outcomes (PROs). However, there is a need to know what the patients think about these revolutionary drugs.

The aim of this multicenter cross-sectional study was to evaluate the expectations of the patients about long-acting antiretroviral agents and how they would like to receive them.

Study Design and methods

We carried out an anonymous online survey through Google modules, asking HIV positive people to judge their relationship with daily antiretroviral therapy (ART) and to give their opinion about long-acting drugs. The survey was open for compilation during a week in June 2020. The patients were invited to linked to the survey by whatsapp or other social messages or during the visit. The median time spent to complete the survey was < 2 minutes.

26 little and large clinical centre and some patients organizations were involved along our country with the aim to have a representative picture of the opinion of the Italian patients (fig.1).

We also collected data about the age of the patients, the centre where they are followed, time passed since the diagnosis and their compliance.

Results

We collected data about 242 patients, 58 females (24.0%), 182 males (75.2%) and 2 transenders (0.8%), with an age ranging from 18 to 69 years. Age distribution is reported in fig 2.

58.7% of the enrolled patients were infected from more than 10 years. More than half was taking a single tablet antiretroviral regimen (fig. 3), 48% reported suboptimal adherence during the last year (more than half of them reported 3 or more missing dose/year).

The majority of the interviewed patients (81.8%) have a good relationship with ART; however, 33.6% of them considers daily ART an obligation and a restriction to their freedom. 143 patients (59.1%) knew about long-acting before this interview, and 215 patients (88.8%) are interested in these new drugs (fig.4).

Moreover, 156 patients (64.5%) states that their interest would not decrease even though the drugs would be administered only at HIV outpatient clinics.

Conclusion

The data emerging from our survey reveal that around 90% of the answering patients are interested in changing their actual treatment with a long acting one. We were surprised to find out that a so high number of subject taking a single tablet regimen are ready to change their tablets with a series of injections.

Actually, we can estimate that in Italy 150,000 patients are on ART. If we assume that only a quarter of the patients showing a so high interest in this new formulation could be treated, it would be necessary to rethink the organization of the outpatient unit or identify alternative methods to manage a so high daily number of injections.

Moreover, for the first time to our knowledge, a so high number of patients showed an enthusiastic response to the new opportunity to be treated directly at home.

The introduction of these new drugs could be revolutionary and represent another step towards life and treatment simplification for people living with HIV infection.